Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus-Reference-Cited by-同舟云学术

Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus

Published:2022-06-29 Issue:6 Volume:5 Page:e2219407
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Tan Darren Jun Hao¹,Ng Cheng Han¹,Tay Phoebe Wen Lin¹,Syn Nicholas¹,Muthiah Mark D.¹²³,Lim Wen Hui¹,Tang Ansel Shao Pin¹,Lim Kai En¹,Lim Grace En Hui⁴,Tamaki Nobuharu⁵,Kim Beom Kyung⁵⁶⁷,Teng Margaret Li Peng¹²³,Fung James⁸,Loomba Rohit⁹,Nguyen Mindie H.¹⁰,Huang Daniel Q.¹²³⁹

Affiliation:

1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore

2. Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore

3. National University Centre for Organ Transplantation, National University Health System, Singapore

4. Lee Kong Chian School of Medicine, Nanyang Technological University, Sinagpore

5. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan

6. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

7. Yonsei Liver Center, Severance Hospital, Yonsei University Health System, Seoul, South Korea

8. Division of Liver Transplantation, Department of Surgery, Queen Mary Hospital, Hong Kong

9. NAFLD (Nonalcoholic Fatty Liver Disease) Research Center, Division of Medicine, University of California, San Diego, La Jolla

10. Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2793772/tan_2022_oi_220558_1655908696.98483.pdf

Reference67 articles.

1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.;GBD 2019 Diseases and Injuries Collaborators;Lancet,2020

2. Development of hepatocellular carcinoma in patients with suppressed viral replication: changes in risk over time.;Udompap;Clin Liver Dis (Hoboken),2020

3. Hepatitis B: who to treat? a critical review of international guidelines.;Huang;Liver Int,2020

4. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.;Chen;JAMA,2006

5. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.;Papatheodoridis;J Hepatol,2015

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial;Trials;2024-01-05

2. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma;Journal of Clinical Oncology;2024-01-04

3. Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation;Public Health;2024-01

4. The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma;Hepatobiliary Surgery and Nutrition;2023-12

5. Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection;JAMA Network Open;2023-10-31